"Hanmi to Fulfill Shareholder Return Commitment... Plans Cash Dividend with Over 20% Return Rate"

Hanmi Science, Hanmi Pharmaceutical, and JVM
Strengthening Shareholder Returns on the Back of Record-Breaking Results

Hanmi Group announced on March 16 that, bolstered by record-breaking performances last year from its holding company and major affiliates, it will expand its cash dividends to enhance shareholder value.

This dividend decision faithfully implements the shareholder return policy officially announced by Hanmi Group at its corporate briefing, 'Hanmi Vision Day,' in December of last year. Hanmi Science is planning a total shareholder return rate of 30%, Hanmi Pharmaceutical 20%, and JVM more than 20%.

Exterior view of Hanmi Pharmaceutical Group headquarters in Songpa-gu, Seoul. Hanmi Pharmaceutical

This cash dividend plan will be submitted for approval at each company’s regular shareholder meeting on March 31, and will be executed following final resolution.

The cash dividend amounts are as follows: Hanmi Science – KRW 300 per common share (dividend yield of 0.79%); Hanmi Pharmaceutical – KRW 2,000 per common share (dividend yield of 0.40%); and JVM – KRW 650 per common share (dividend yield of 2.5%).

Jae Kyo Kim, CEO of Hanmi Science, stated, "We are maximizing future business development and strategic growth opportunities to enhance corporate value, while also actively working to improve shareholder value through both financial and non-financial means. Based on our stable financial structure, we will continue to expand our shareholder-friendly policies by maintaining a balance between growth investments and shareholder returns."

Meanwhile, Hanmi Group unveiled its 'New Vision' with the aim of achieving a combined affiliate revenue of KRW 5 trillion by 2030, based on a stable management environment. At 'Hanmi Vision Day,' the group presented a growth strategy roadmap focused on four key areas: obesity, anti-aging, digital healthcare, and robotics.

Hanmi Science is pursuing an operating margin of over 25% by 2030, driving high value-added business expansion in the medical device and beauty care sectors, as well as growth across group affiliates. Hanmi Pharmaceutical aims for an operating margin of over 20% through successful licensing-out deals and the launch of blockbuster new drugs both domestically and internationally, leveraging its global R&D capabilities. JVM is targeting an operating margin exceeding 20% by expanding overseas sales in North America and Europe and growing its software business segment.

This content was produced with the assistance of AI translation services.